Prophylactic administration of Methylene Blue in patients at high risk for the Vasoplegic Syndrome in Cardiac surgery: randomized clinical trial

Hospital das clínicas da Faculdade de Medicina da Universidade de São Paulo0 个研究点开始时间: 2024年2月17日最近更新: 2024年3月5日

适应症

试验速览

暂无简介。

•Age 18 years or older; cardiac surgery with cardiopulmonary bypass; EUROSCORE II between 4% and 15%; patient undergoing double valve repair and/or double valve replacement surgery or reoperation in valve surgery or combined surgery (coronary bypass graft with valve surgery) or valve replacement due to endocarditis.

•Refusal to participate in the study; patient involved in another clinical trial; emergency surgery; minimally invasive or transcatheter cardiac surgery; cardiac surgery with no cardiopulmonary bypass; change in surgical planning, such as single valve replacement/repair or isolated revascularization; previous or current use of selective serotonin reuptake inhibitor drugs, or selective and non-selective monoamine oxidase inhibitor drugs, or non-selective heterocyclic monoamine reuptake inhibitor drugs; patient with glucose-6-phosphate dehydrogenase deficiency or other hemolytic disease; previous history of hypersensitivity to methylene blue; acute liver dysfunction; pregnancy or potential risk of pregnancy; current use of vasoactive amines.

发起方

Hospital das clínicas da Faculdade de Medicina da Universidade de São Paulo